iRhythm Technologies, Inc
IRTCiRhythm Technologies, Inc. is a healthcare company specializing in the development and commercialization of wearable biosensing devices and cloud-based data analysis tools for cardiac monitoring. Its flagship product, the Zio service, provides ambulatory ECG monitoring to detect arrhythmias, enabling improved diagnosis and management of cardiovascular conditions. Founded in 2006 and headquartered in San Francisco, iRhythm aims to enhance patient care through innovative digital health solutions.
Company News
NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.
The global cardiac monitoring devices market is projected to grow from USD 21 billion in 2024 to USD 32 billion by 2032, driven by rising cardiovascular disease prevalence, technological advancements in remote monitoring, and increasing health awareness.
iRhythm Technologies reported strong Q1 2025 results, with revenue growing 20.3% year-over-year driven by increased demand for its Zio services. The company's gross margin also improved, and it provided an upbeat guidance for fiscal 2025. Analysts have turned bullish on the stock, with Wells Fargo upgrading it to Overweight.
An executive at iRhythm Technologies sold $148,332 worth of the company's stock to cover tax obligations related to the vesting of Restricted Stock Units. The executive still retains a substantial holding of 27,255 shares in the company.
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
